Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA
- 1 October 2013
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 31 (44), 5047-5054
- https://doi.org/10.1016/j.vaccine.2013.08.088
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year OldsThe Pediatric Infectious Disease Journal, 2013
- Optimization and Validation of a Plaque Reduction Neutralization Test for the Detection of Neutralizing Antibodies to Four Serotypes of Dengue Virus Used in Support of Dengue Vaccine DevelopmentThe American Journal of Tropical Medicine and Hygiene, 2013
- Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 yearsHuman Vaccines & Immunotherapeutics, 2012
- Dominant Cross-Reactive B Cell Response during Secondary Acute Dengue Virus Infection in HumansPLoS Neglected Tropical Diseases, 2012
- Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in HumansThe American Journal of Tropical Medicine and Hygiene, 2011
- From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccineVaccine, 2011
- Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO®) induced neutralizing antibody titersVaccine, 2011
- Dengue, Urbanization and Globalization: The Unholy Trinity of the 21st CenturyTropical Medicine and Health, 2011
- Inferring the Serotype Associated with Dengue Virus Infections on the Basis of Pre‐ and Postinfection Neutralizing Antibody TitersThe Journal of Infectious Diseases, 2010
- Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteersVaccine, 2001